Mark O’Donnell Joins Argonaut Manufacturing Services Board
Carlsbad, CA, Nov 05, 2019 – Argonaut Manufacturing Services announced today that Mark O’Donnell has been appointed to the company’s Board of Directors. Mr. O’Donnell joins the Argonaut Board with over 40 years of experience in global operations. Most recently, he served as Executive Vice President of Global Operations at Thermo Fisher Scientific.
Mr. O’Donnell brings extensive leadership experience, global operations expertise, and a history of making supply chains a competitive differentiator. In addition to leading global operations for Thermo Fisher Scientific, he successfully led teams at Perkin Elmer, Applied Biosystems, and Life Technologies.
“We are honored to welcome Mark to our Board of Directors at this key point in Argonaut’s growth,” stated Wayne Woodard, Argonaut Chief Executive Officer. “As a highly respected and seasoned operations executive, we look forward to Mark’s expert engagement in guiding Argonaut as we build solutions for our contract manufacturing clients.”
One of Mr. O’Donnell’s major achievements at Life Technologies and Thermo Fisher Scientific was investment in Green Initiatives that are aligned with cost savings and environmental waste reduction. This aligns with Argonaut Manufacturing Services “Go Ambient” lyophilization programs for clients to lyophilize their antibodies, oligos, enzymes, or reagents to reduce or remove the cold chain and increase shelf life at ambient temperatures. The outcome is green shipping that reduces global cold chain costs, emissions and shipping waste – all while improving customer satisfaction and product storability.
“I am excited to join the Argonaut Board,” stated Mr. O’Donnell. “As an innovative CMO, Argonaut has cutting edge solutions for aseptic biopharma drug product manufacturing, as well as a leadership position in molecular diagnostics and life science cGMP manufacturing.”
Eric Blair, Argonaut’s Chief Commercial Officer, commented “Mark joins our board at an important time in Argonaut’s history. We are scaling in three different business areas to serve our clients. Our recent installation of one of the most advanced aseptic drug vial fill platforms on the West Coast of the US is a great example of a state-of-the-art drug product manufacturing capability that will serve premier pharma organizations and innovative biopharma companies. Our acquisition of LyoGen in 2018 is giving us novel lyophilization capabilities for our clients to manufacture diagnostic assays that can significantly reduce costs while taking a leadership position to positively impact green initiatives in our industry. We have also demonstrated our ability to ‘lift and shift’ entire portfolios as the manufacturing partner for large publicly traded life science and molecular diagnostic companies. It is a privilege to have Mark O’Donnell on Argonaut’s board to help us better serve our clients and to strategically grow our business.” Mark joined the board effective November 1, 2019.
Argonaut is backed by Telegraph Hill Partners. To learn more about any services provided by Argonaut Manufacturing Services, visit www.argonautms.com.
Argonaut Manufacturing Services is an FDA registered, ISO 13485:2016 cGMP contract manufacturing organization dedicated to providing custom manufacturing and supply chain solutions for life science, molecular diagnostics, and biopharmaceutical companies. Life Sciences and Molecular Diagnostics services include formulation, filling, lyophilization, and kitting, while biopharmaceutical services feature state-of-the-art automated aseptic fill-finish equipment for sterile injectable drugs. All projects are supported by a full analytical quality control service offering and global shipping logistics. From procurement through pick-pack-ship, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs.
